Prion

| Main Article
| Discussion
| Related Articles  [?]
| Bibliography  [?]
| External Links  [?]
| Citable Version  [?]

|
|
|
|
|
|
|
|

This editable Main Article is under development and subject to a disclaimer.

[edit intro]

## Contents

* 1 PrP and the prion hypothesis
* 2 Prions in yeast and other fungi
* 3 Molecular properties of prions
* 4 Classification
* 5 Therapeutic strategies
* 6 Attribution
* 7 References

A prion (pronounced 'pree-on'), short for proteinaceous infectious particle, is a unique type of infectious agent, made only of protein. Prions are abnormally structured forms of a host protein that can convert normal molecules of the protein into the abnormal structure. Although the exact mechanisms of their actions and propagation are unknown, it is now commonly accepted that prions are responsible for a number of previously known but little-understood diseases classified as transmissible spongiform encephalopathy diseases (TSEs). These include scrapie (a disease of sheep), Creutzfeldt-Jakob disease (CJD), and bovine spongiform encephalopathy (BSE or mad cow disease). [1] These diseases affect the structure of brain tissue and all are fatal and untreatable.

Proteins showing prion behaviour are also found in some fungi. Some fungal prions may not be associated with any disease state and may have an evolutionary advantage for their hosts. So far, all prions discovered are believed to infect and propagate by formation of an amyloid fold. However, as any infectious protein particle would be defined as a prion, other mechanisms may be possible.

Prion Diseases (TSEs)

ICD-10  | A81
ICD-9  | 046

## PrP and the prion hypothesis[edit]

Radiation biologist Tikvah Alper and physicist J.S. Griffith developed the theory in the 1960s that some TSEs are caused by an infectious agent devoid of nucleic acid.[2][3] This theory was developed to explain the discovery that the mysterious infectious agent causing the diseases scrapie and Creutzfeldt-Jakob Disease, which resisted ultraviolet radiation (which breaks down nucleic acids \- present in viruses and all living things), yet responded to agents that disrupt proteins.

A breakthrough occurred in 1982 when researchers led by Stanley B. Prusiner of the University of California, San Francisco purified infectious material and confirmed that the infectious agent consisted mainly of a specific protein. Prusiner coined the word 'prion' for the infectious agent, by combining the first two syllables of the words 'proteinaceous' and 'infectious'. While the infectious agent was named a prion, the specific protein that the prion was made of was named PrP ('prion-related protein'). Prusiner was awarded the Nobel Prize in physiology or medicine in 1997 for this research.[4]

PrP is found throughout the body, even in healthy people and animals. However, the PrP in infectious material (i.e. which forms prions) has a different structure and is resistant to proteases, the enzymes in the body that can normally break down proteins. The normal form of the protein is called PrPC, while the infectious form is called PrPSc— the 'C' refers to 'cellular' PrP, while the 'Sc' refers to 'scrapie,' a prion disease occurring in sheep. PrPC is found on the membranes of cells, though its normal function has not been fully resolved. Since the original hypothesis was proposed, a gene for PrP has been isolated: the Prnp gene.[5] Some prion diseases (TSEs) can be inherited, and in all inherited cases there is a mutation in the Prnp gene. Many different Prnp mutations have been identified and it is thought that the mutations make PrPC more likely to spontaneously change into the PrPSc (disease) form. TSEs are the only diseases that can be sporadic, genetic or infectious; for more information see the article on TSEs.

Although the identity and general properties of prions are now well-understood, the mechanisms of prion infection and propagation remains mysterious. It is generally assumed that PrPSc directly interacts with PrPC to cause the normal form of the protein to rearrange its structure (enlarge the diagram above for an illustration of this mechansism). One idea, the "Protein X" hypothesis, is that an as-yet unidentified cellular protein (Protein X) enables the conversion of PrPC to PrPSc by bringing a molecule of each of the two together into a complex.[6]

Before Prusiner's insight, all known pathogens (bacteria, viruses, etc.) contained nucleic acids that are necessary for reproduction. The prion hypothesis was highly controversial, because it seemed to contradict the so-called 'central dogma of modern biology' that asserts all living organisms use nucleic acids to reproduce. The 'protein-only hypothesis' -- that a protein structure (which, unlike DNA, has no obvious means of replication) could reproduce itself -- was initially met with scepticism. However, evidence has steadily accumulated in support of this hypothesis, and it is now widely accepted. Rather than contradicting the central role of DNA, however, the prion hypothesis suggests a special case in which merely changing the shape, or conformation, of a protein (without changing its amino acid sequence) can alter its biological properties.

## Prions in yeast and other fungi[edit]

For more information, see: Fungal prions.

Prion-like proteins that behave like PrP are found naturally in some fungi and non-mammalian animals. Some of these are not associated with any disease, and might have a useful role. Research into fungal prions has given strong support to the protein-only hypothesis for mammalian prions by showing that the prion form of a protein can directly convert the normal form of that protein. It has also shed some light on prion domains, which are regions in a protein that promote the conversion. Fungal prions have helped to suggest mechanisms of conversion that may apply to all prions.

## Molecular properties of prions[edit]

Much of our knowledge of how prions work at a molecular level comes from biochemical analysis of yeast prion proteins. A typical yeast prion protein contains a region (protein domain) with many repeats of the amino acids glutamine (Q) and asparagine (N); these Q/N-rich domains form the core of the prion's structure. Ordinarily, yeast prion domains are flexible and lack a defined structure. When they convert to the prion state, several molecules of a particular protein come together to form a highly structured amyloid fiber. The end of the fiber acts as a template for the free protein molecules, causing the fiber to grow. Small differences in the amino acid sequence of prion-forming regions lead to distinct structural features on the surface of prion fibers. As a result, only free protein molecules that are identical in amino acid sequence to the prion protein can be recruited into the growing fiber. This specificity might explain why transmission of prion diseases from one species to another (such as from sheep to cows or from cows to humans) is so rare.

The mammalian prion proteins do not resemble the prion proteins of yeast in their amino acid sequence. Nonetheless, the basic structural features (formation of amyloid fibers and a highly specific barrier to transmission between species) are shared between mammalian and yeast prions. The prion variant responsible for mad cow disease has the remarkable ability to bypass the species barrier to transmission.

The figure at right shows a model of two conformations of PrP; on the left is the known, normal conformation of the structured (C-terminal) region of PrPC (to explore/download see the RCSB Protein Databank). Some of the protein (the N-terminal region) is not shown here as it does not have a fixed structure in aqueous solution. The structured domain shown is mainly made of three spirals called alpha helices (pink), with two short 'flat' regions of beta sheet structure (green). On the right is a proposed model of how the abnormal PrPSc form might look. Although the exact 3D structure of PrPSc is not known, there is increased β sheet content (green arrows) in the prion version of the molecule.[7] These β sheets are thought to lead to amyloid aggregation.

## Classification[edit]

Mammalian prions, agents of spongiform encephalopathies

Disease name | Natural host | Prion name | PrP isoform
Scrapie| Sheep and goats| Scrapie prion| OvPrPSc
Transmissible mink encephalopathy (TME)| Mink| TME prion| MkPrPSc
Chronic wasting disease (CWD)| Mule Deer and Red Deer| CWD prion| MDePrPSc
Bovine spongiform encephalopathy (BSE)| Cattle| BSE prion| BovPrPSc
Feline spongiform encephalopathy (FSE)| Cats| FSE prion| FePrPSc
Exotic ungulate encephalopathy (EUE)| Nyala and greater kudu| EUE prion| NyaPrPSc
Kuru| Humans| Kuru prion| HuPrPSc
Creutzfeldt-Jakob disease (CJD)| Humans| CJD prion| HuPrPSc
(New) Variant Creutzfeldt-Jakob disease (vCJD, nvCJD)| Humans| vCJD prion| HuPrPSc
Gerstmann-Sträussler-Scheinker syndrome (GSS)| Humans| GSS prion| HuPrPSc
Fatal familial insomnia (FFI)| Humans| FFI prion| HuPrPSc

## Therapeutic strategies[edit]

Recently Japanese scientists at the Obihiro University of Agriculture and Veterinary Medicine developed one of the first strategies to delaying the onset of disease. They found that sulfated glycosaminoglycans (GAGs) and sulfated glycans inhibit formation of protease resistant protein in cells and prolong the incubation time of scrapie-infected animals. Among the glycopyranosides and their polymers examined, monomeric 4-sulfo-N-acetyl-glucosamine (4SGN), and two glycopolymers, poly-4SGN and poly-6-sulfo-N-acetyl-glucosamine (poly-6SGN), inhibited PrPSc formation with 50% effective doses below 20 microg/ml, and their inhibitory effect became more evident with consecutive treatments. Structural comparisons suggested that a combination of an N-acetyl group at C-2 and an M-sulfate group at either O-4 or O-6 on glucopyranoside might be involved in the inhibition of PrPSc formation. Furthermore, polymeric but not monomeric 6SGN inhibited PrPSc formation, suggesting the importance of a polyvalent configuration in its effect. These results indicate that the synthetic sulfated glycosides are useful not only for the analysis of structure-activity relationship of GAGs but also for the development of therapeutics for prion diseases.[8]

## Attribution[edit]

Some content on this page may previously have appeared on Wikipedia.

## References[edit]

1. ↑ (2001) "Prion diseases of humans and animals: their causes and molecular basis". Annu Rev Neurosci 24: 519-50.
2. ↑ (1967 May 20) "Does the agent of scrapie replicate without nucleic acid?". Nature 214 (90): 764-6. PMID 4963878 DOI:10.1038/214764a0.
3. ↑ (1967 Sep 2) "Self-replication and scrapie". Nature 215 (105): 1043-4. PMID 4964084 DOI:10.1038/2151043a0.
4. ↑ (1982 Apr 9) "Novel proteinaceous infectious particles cause scrapie". Science 216 (4542): 136-44.
5. ↑ (1985 Apr) "A cellular gene encodes PrP 27-30 protein". Cell 40 (4): 735-46.
6. ↑ (1995 Oct 6) "Prion propagation in mice expressing human and chimeric PrP transgenes implicates the interaction of cellular PrP with another protein". Cell 83 (1): 79-90.
7. ↑ (1993 Dec 1) "Conversion of alpha-helices into beta-sheets features in the formation of scrapie prion protein". PNAS USA 90 (23): 10962-6.
8. ↑ (2006 Oct 20) "Inhibition of PrPSc Formation by Synthetic M-Sulfated Glycopyranosides and Their Polymers". Biochem Biophys Res Commun 349 (2): 485-491.